

# 1 Buttermilk and Krill Oil Phospholipids Improve 2 Hippocampal Insulin Resistance and Synaptic Signaling 3 in Aged Rats 4

5 Joao Tomé-Carneiro<sup>1§</sup>, M. Carmen Crespo<sup>1§</sup>, Emma Burgos-Ramos<sup>3</sup>, Cristina Tomas-  
6 Zapico<sup>4,5</sup>, Cesar Venero<sup>6</sup>, Inmaculada Pereda-Pérez<sup>6-7</sup>, Shishir Baliyan<sup>6</sup>, Azucena  
7 Valencia<sup>6</sup>, Alba García-Serrano<sup>8</sup>, Javier Fontecha<sup>8</sup>, Alberto Dávalos<sup>2\*</sup>, Francesco  
8 Visioli<sup>1,9\*</sup>

9 <sup>1</sup>Laboratory of Functional Foods and <sup>2</sup>Laboratory of Epigenetics of Lipid Metabolism,  
10 Madrid Institute for Advanced Studies (IMDEA)-Food, CEI UAM + CSIC, Madrid-  
11 28049, Spain; <sup>3</sup>Área de Bioquímica, Universidad de Castilla-La-Mancha, Toledo 45071,  
12 Spain; <sup>4</sup>Department of Functional Biology (Physiology), University of Oviedo, Oviedo  
13 33006, Spain; <sup>5</sup> Universidad Autónoma de Chile, Santiago 7500912, Chile. <sup>6</sup>Department  
14 of Psychobiology, Faculty of Psychology, UNED, 28040 Madrid, Spain; <sup>7</sup>Faculty of  
15 Biosanitary Sciences, Francisco de Vitoria University, Pozuelo de Alarcón, 28223  
16 Madrid, Spain <sup>8</sup>Institute of Food Science Research, Spanish National Research Council  
17 (CIAL, CSIC-UAM), Bioactivity and Food Analysis Department, Food Lipid Biomarkers  
18 and Health, Campus of Autonomía University of Madrid, 28049 Madrid, Spain;  
19 <sup>9</sup>Department of Molecular Medicine, University of Padova, Padova-35121, Italy;

20 <sup>§</sup>These authors contribute equally to this work.

21 \*Corresponding authors: Madrid Institute for Advanced Studies (IMDEA)-Food,  
22 Madrid, Spain

23 e-mails: [francesco.visioli@imdea.org](mailto:francesco.visioli@imdea.org) (FV) and [alberto.davalos@imdea.org](mailto:alberto.davalos@imdea.org) (AD).

24 Keywords: insulin, hippocampus, phospholipids, buttermilk, krill oil

25

26 **Abstract**

27 Impaired glucose metabolism and mitochondrial decay greatly increase with age,  
28 when cognitive decline becomes rampant. No pharmacological or dietary intervention has  
29 proven effective, but proper diet and lifestyle do postpone the onset of neurodegeneration  
30 and some nutrients are being investigated. We studied insulin signaling, mitochondrial  
31 activity and biogenesis, and synaptic signaling in the hippocampus and cortex following  
32 dietary supplementation with bioactive phospholipid concentrates of krill oil (KOC),  
33 buttermilk fat globule membranes (BMFC), and a combination of both in aged rats. After  
34 3 months of supplementation, although all groups of animals showed clear signs of  
35 peripheral insulin resistance, the combination of KOC and BMFC was able to improve  
36 peripheral insulin sensitivity. We also explored brain energy balance. Interestingly, the  
37 hippocampus of supplemented rats—mainly when supplemented with BMFC or the  
38 combination of KOC and BMFC—showed an increase in intracellular adenosine  
39 triphosphate (ATP) levels, whereas no difference was observed in the cerebral cortex.  
40 Moreover, we found a significant increase of brain-derived neurotrophic factor (BDNF)  
41 in the hippocampus of BMFC+KO animals. In summary, dietary supplementation with  
42 KOC and/or BMFC improves peripheral and central insulin resistance, suggesting that  
43 their administration could delay the onset of these phenomena. Moreover, n-3 fatty acids  
44 (FAs) ingested as phospholipids increase BDNF levels favoring an improvement in  
45 energy state within neurons and facilitating both mitochondrial and protein synthesis,  
46 which are necessary for synaptic plasticity. Thus, dietary supplementation with n-3 FAs  
47 could protect local protein synthesis and energy balance within dendrites, favoring  
48 neuronal health and delaying cognitive decline associated to age-related disrepair.

## 49 **Introduction**

50 It has been shown that insulin controls not only whole-body energy and glucose  
51 homeostasis in the periphery of the human body but also exerts specific effects in the  
52 brain (Ghasemi et al., 2013; Kleinridders et al., 2014). In fact, impaired glucose  
53 metabolism or mitochondrial dysfunction are among the major pathological changes  
54 observed in various neurodegenerative diseases (Bhat et al., 2015), which is in accordance  
55 with an increase in insulin resistance with age (Akintola and van Heemst, 2015).

56 Insulin signaling in the brain follows the same steps described for peripheral tissues,  
57 and its receptor is expressed in neurons and glial cells in different brain regions. Among  
58 them, hippocampus and temporal cortex shows the highest levels of insulin receptor  
59 expression, indicating the important role of insulin in learning and memory (Akintola and  
60 van Heemst, 2015; Unger et al., 1991). Previous works have demonstrated that the  
61 glucose flux might regulate hippocampal memory processing through an increase of  
62 Glut4 translocation in this region (Pearson-Leary and McNay, 2016). Thus, insulin  
63 resistance in brain, due to impaired insulin receptor signaling and/or decreased insulin  
64 transport through the blood-brain-barrier, could severely affect normal cognitive  
65 processes. This becomes important when considering risk factors associated with insulin  
66 resistance, such as obesity, poor diet, physical inactivity, aging and genetic  
67 predisposition, that were further related with cognitive dysfunction and dementia  
68 (Biessels and Reagan, 2015; Bartke, 2008). Most of these factors are modifiable,  
69 indicating that prevention is crucial to avoid detrimental effects of insulin resistance.

70 Mediterranean diet has been largely associated with lower incidence of age-related  
71 diseases, such as Alzheimer's disease (AD). For instance, amelioration of insulin  
72 signaling was seen after treatment with hydroxytyrosol, the dominant polyphenol in extra  
73 virgin olive oil, in an astrocytic model of AD (Crespo et al., 2017b), suggesting that diet  
74 fats could play an important role at this level. Moreover, during aging, there is a constant

75 loss of the polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) in the  
76 nervous system, both in neurons and glial cells, which has been associated with  
77 pathologies such as senile dementia and AD (Jicha and Markesbery, 2010). For this  
78 reason, DHA supplementation to this risk group is of special relevance, aiming to prevent  
79 or alleviate the symptoms of these and other pathologies.

80       FAO and WHO recommend a daily intake in adults of at least 500 mg / day EPA  
81 (eicosapentaenoic acid) + DHA (FAO et al., 2012). However, the current  
82 recommendations aim to increase the consumption of both free fatty acids (FFAs) through  
83 the intake of fatty fish, functional foods, nutraceuticals or consuming supplemented foods  
84 (Riediger et al., 2009). Regarding this, n-3 FAs associated to phospholipids are more  
85 bioavailable to different tissues, such as the brain (Wijendran et al., 2002). For this reason,  
86 krill oil is an adequate supplement, since it is rich in n-3 FAs incorporated into  
87 phosphatidylcholine (PC) and its beneficial effects have been described on blood lipids  
88 (Berge et al., 2014), inflammation (Deutsch, 2007), and even at cognitive function levels  
89 in the elderly (Konagai et al., 2013).

90       Other source of FFAs is milk fat. The milk fat globule consists of a core, mainly  
91 composed of triacylglycerides (TAG; 98%–99%), and different concentrations of lipid  
92 compounds such as diacylglycerides, monoacylglycerides, FFAs, and cholesterol. This  
93 core is surrounded by the milk fat globule membrane (MFGM), which contains different  
94 phospho- and sphingolipids and has potential positive effects on human health, namely  
95 in neurological pathologies (Castro-Gomez et al., 2015). Buttermilk (BM), a byproduct  
96 obtained from butter manufacturing with a high content of MFGM, accounts for a  
97 significantly increased polar lipids content that may reach up to 20% of total lipid  
98 concentration (Castro-Gomez et al., 2016), which could be further increased by using

99 food-grade solvents to obtain BM lipids and isolate different BM fractions (Castro-  
100 Gomez, 2016).

101 One possible application of these BM fractions might be as functional food rich in  
102 phospho- and sphingolipids, along with linolenic acid, DHA and EPA precursor.  
103 Particularly, phosphatidylserine (PS) and sphingomyelin (SM) are present in this  
104 fractions, playing PS an important role in cellular functions including mitochondrial  
105 membrane integrity, release of presynaptic neurotransmitters, activity of postsynaptic  
106 receptors and activation of Protein Kinase C in memory formation (Osella, Re et al.,  
107 2008). Also, decrease of SM in myelin content in the brain has been related to the slowing  
108 in the speed of the cognitive process associated with aging (Lu, Lee et al., 2011).

109 Due to the loss of PUFA during of aging, dietary supplementation with Butter milk  
110 fat concentrate (BMFC) and Krill oil Concentrate (KOC) could be an approach to  
111 overcome this deficit. For this reason, we aimed to study insulin signaling in hippocampus  
112 and cortex in response to dietary supplementation with bioactive phospholipids  
113 concentrates of krill oil (rich on 3-n FA and PC), BMFC (rich on linolenic acid, PS and  
114 SM) or a mix of both in aged rats. Mitochondrial activity and biogenesis, and synaptic  
115 signaling were also assessed.

116

## 117 **Materials and methods**

### 118 **Materials**

119 Buttermilk and krill oil concentrates (BMFC and KOC, respectively) and the  
120 elaboration of daily doses in the form of a jelly lollipop were produced at the Institute of  
121 Food Science Research (CIAL, Madrid, Spain). Briefly, BM fat was extracted by  
122 pressurized liquid extraction (PLE) using an accelerated solid ASE-200 extractor (Dionex  
123 Corp. Sunnyvale, CA). Fifteen grams of powdered BM were mixed with sand (1:1, by  
124 weight) and loaded into a stainless steel extraction cell. To obtain the maximum BMfat

125 yield, the extraction procedure was based on the optimized PLE method of Castro-Gomez  
126 et al. 2014. The lipid extracts were capped under nitrogen and stored at  $-35^{\circ}\text{C}$ .

## 127 **Animals**

128 This research project followed the Guide for the Care and Use of Laboratory Animals,  
129 published by the US National Research Council (Eight Edition, 2010). Animal care was  
130 according to the standards proposed by the European Community (86/609/EEC). Animal  
131 experiments were approved by the Animal Experimentation Committee of the National  
132 University of Distance Education. A total of 41 male Wistar rats (9 months of age) were  
133 purchased from Charles River Laboratories (Barcelona, Spain). Rats were distributed  
134 randomly in groups of two per box and maintained in a 12:12 light-dark cycle (8 a.m. to  
135 8 p.m.), with constant temperature and humidity conditions ( $22 \pm 2^{\circ}\text{C}$  and 50% RH),  
136 during the following 9 months. Food and water were given ad libitum.

## 137 **Experimental design and diets**

138 Since 18-months' rats are considered old and present a variety of cognitive deficiency  
139 (CD) symptoms associated with aging, when animals reached this age they were  
140 randomly assigned to four experimental groups (**Table 1**). All groups were given a  
141 standard diet EURodent (LabDiet, San Luis, Misuri) plus a group-specific supplement  
142 intake in form of frozen strawberry jellies: 1) control group - refined olive oil, 2) BMFC  
143 group – concentrate of phospholipids from dairy fat globule membrane, 3) KOC group -  
144 concentrate of krill oil (KO) omega-3 fatty acids (eicosapentaenoic acid (EPA),  
145 and docosahexaenoic acid (DHA)) enriched phospholipids, and 4) BMFC + KOC group  
146 – one identical jelly containing the same treatment from group 2 and group 3 given  
147 simultaneously. Detailed composition of different lipid classes is described in **Table 2**.  
148 Full intake of supplements in form of frozen strawberry jellies was visually verified every  
149 day.

150 The nutritional composition of the daily diet of the four experimental groups is shown  
151 in **Table 3**. Rats were sacrificed by decapitation after three months of supplementation,  
152 following a 12-hour fast. Hippocampus and temporal cortex were quickly extracted,  
153 washed in PBS, snap-frozen in liquid nitrogen, and stored at -80 °C. Blood samples were  
154 collected with heparin (100UI/mL), centrifuged for plasma collection at 1500 xg for 15  
155 minutes and stored at -80 °C until used.

#### 156 **Determination of circulating biochemical parameters.**

157 Concentration of plasma glucose was measured with commercial kits (WAKO, Neuss,  
158 Germany) and insulin levels were determined by an ELISA kit (Rat Insulin, 96-well plate  
159 assay, Millipore, Madrid, Spain), according to the manufacturer's instructions. The index  
160 of insulin resistance, a.k.a. homeostasis model assessment ratio (HOMA-R), was  
161 calculated using the following formula:

$$162 \text{ HOMA} = \text{fasting glucose (mmol/L)} \times \text{fasting insulin } (\mu\text{IU/mL}) / 22.5.$$

#### 163 **Measurement of ATP levels in tissue samples**

164 To evaluate the energy status of the cells in the hippocampus and temporal cortex, a  
165 bioluminescent assay was used to assess intracellular adenosine triphosphate (ATP) levels  
166 (Sigma- Aldrich, St Lois MO, USA). The homogenized samples were previously filtered  
167 through 0.22  $\mu\text{m}$  filters (Millipore Corp., Bedford, Mass.). The kit was performed  
168 according to the manufacturer's protocol and luminescence was measured using a  
169 microplate reader at 570 nm (Biochrom Asys UVM 340, Cambridge, UK).

#### 170 **RNA isolation and qRT-PCR**

171 Total RNA extraction from both tissues were performed according to the  
172 manufacturer's instructions for the miRNeasy Mini kit (Qiagen, Madrid, Spain),  
173 including DNA digestion. RNA quantity and purity were analysed using a NanoDrop ND-  
174 1000 UV-Vis Spectrophotometer (Thermo Fisher Scientific Inc., Spain) and RNA

175 integrity using an Agilent's 2100 bioanalyser. Total RNA was converted into first strand  
176 cDNA using miScript®II Reverse Transcription kit, Qiagen (Izasa, Barcelona, Spain)  
177 according to the manufacturer's guidelines.

### 178 **Electron transport chain array**

179 A Mitochondria energy metabolism (SAB Target List) H384 Predesigned 384-well  
180 panel (Bio-Rad, Madrid, Spain) was carried out. Five samples of each experimental group  
181 with the highest RINs were selected to perform the assay. The pre-designed plates were  
182 formed by 87 genes, within these 10 are reference genes, 27 genes belong to complex I;  
183 4 to complex II, 6 to complex III, 15 to complex IV, 18 to complex V, and 7 are associated  
184 with the respiratory chain, although they are not included in any complex.

185 qRT-PCR reactions were performed using miScript SYBR Green PCR Kit from  
186 Qiagen (Izasa, Madrid, Spain) using a 7900HT Real-Time PCR System (Life  
187 Technologies, Alcobendas, Spain). Cycling conditions were a first step of activation at  
188 95 °C for 15 minutes; 40 cycles of denaturation at 94 °C for 15 seconds, annealing at 58  
189 °C for 30 seconds and a final step for dissociation curve. PPA1 was identified by  
190 NormFinder as the most stable reference gene among 10 other candidates.

### 191 **Determination of synaptoproteins gene expression.**

192 Gene expression analysis of genes encoding proteins involved in the nerve synapses  
193 were performed by qRT-PCR (see above) in a 384-well plate using ABI PRISM 7900HT  
194 real-time PCR system. Cycling conditions were the same as describe above. Specific  
195 primers for each gene were designed using Primer3 software (**Supplementary Table 1**).  
196 Quantification of relative gene expression was performed using the comparative delta Ct  
197 method using GAPDH as reference genes for normalization.

### 198 **Western blot assays**



199 Temporal cortex and hippocampus samples were homogenized with RIPA lysis buffer  
200 containing protease and phosphatase inhibitors (Sigma-Aldrich, Madrid, Spain).  
201 Homogenates were kept at -80°C for 24 h, centrifuged (4 °C, 12000 xg, 30 min) and  
202 supernatants were collected. Total protein concentrations were determined using BCA  
203 protein assay reagent (ThermoFisher Scientific, Madrid, Spain). Equal amounts of protein  
204 (30 µg) were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gel  
205 electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad,  
206 Madrid, Spain). Membranes were blocked with 5% non-fat milk powder in Tris-buffered  
207 saline containing 0.1% Tween-20 (TBS-T) for 2 h at room temperature, and then  
208 incubated overnight at 4 °C with various primary antibodies regarding key components  
209 of the insulin signaling pathway, components of the neurotransmissions and  
210 neurodegenerations (**Supplementary Table 2**) and involved in respiratory  
211 mitochondrial chain (abcam ab110413). Following incubation with appropriate  
212 secondary antibodies protein bands were detected by an enhanced chemiluminescence  
213 method using the ECL kit (Bio-Rad, Madrid, Spain). Normalization of total protein  
214 expression was carried out using GAPDH or with their corresponding total form in the  
215 case of phosphorylated proteins.

## 216 **Statistical analysis**

217 Statistical analyses were carried out using GradPad Prism 7.02 software (GraphPad  
218 Software, Inc., La Jolla, CA, USA). For the gene expression analysis, data was quantified  
219 using the  $\Delta\Delta C_t$  method and fold-change values were reported as  $2^{-(\Delta\Delta C_t)}$ . Data from  
220 independent samples from all experiments was compared by one-way ANOVA using  
221 Tuckey test to compare all study groups. Values of  $p < 0.05$  was considered significant.  
222 Results are presented as means  $\pm$  SEM.

223

## 224 **Results**

### 225 **Combination of BMFC and KOC improves peripheral insulin sensitivity**

226 Aged rats fed with isocaloric diets (**Table 1**) during 3 months did not show any  
227 apparent changes in body weight (data not shown). Since insulin resistance is tightly  
228 associated to aging and cognitive dysfunction (Umegaki et al., 2017), we wondered  
229 whether different dietary supplements affected glycemic profiles. No significant  
230 differences in glucose levels in any of the study groups were observed (**Figure 1A**).  
231 However, glucose levels in all groups indicated that there is an insulin resistance process,  
232 since the normal physiological glucose range is around  $75.4 \pm 5.5$  mg/ml in adults rats  
233 (from 4 months) (Burgos-Ramos et al., 2011). Indeed, the studied aged rats presented  
234 values closed to 150 mg/dl. Along with this, serum insulin concentrations were higher  
235 than in adult rats. Compared to the control group, the combination of BMFC with KOC  
236 reached lower insulin levels (**Figure 1B**). This observation was further confirmed by the  
237 HOMA ratio (**Figure 1C**), suggesting that the mixture improves peripheral insulin  
238 sensitivity.

### 239 **Hippocampal and cortical insulin signaling is increased in high phospholipid** 240 **concentrate diets**

241 Dysregulation of brain insulin signaling has been linked to aging and neurodegenerative  
242 disorders (Biessels and Reagan, 2015; Ghasemi et al., 2013; Kleinridders et al., 2014). To  
243 determine whether the different supplements influence central insulin signaling, we next  
244 evaluated key insulin pathway molecules in hippocampus and cerebral cortex. Protein  
245 analysis from hippocampal samples showed a significant increase in the insulin receptor  
246 subunit IR $\beta$  expression levels both in KOC and BMFC+KOC (**Figure 2A**), whereas the  
247 activated insulin substrate IRS1 was augmented in those groups supplement with BMFC.  
248 This activation mediated by insulin receptor was not observed in the IRS2 protein. Since

249 cytoplasmic insulin signaling is mediated through PI3K, we also explored the expression  
250 levels of the regulatory subunit p85 from this kinase. As seen for IRS1, BMFC  
251 supplementation rose PI3K expression levels. Since the last step of the insulin pathway,  
252 Akt activation, was detected in hippocampal samples of the three experimental groups, it  
253 seems possible that a high phospholipid diet improves hippocampal insulin signaling.  
254 Moreover, cerebral cortex insulin signal analysis showed that this route was also activated  
255 in this area (**Figure 2B**), suggesting that this effect is not only restricted to one brain  
256 region.

257       Activation of the insulin intracellular signaling stimulates the translocation of the  
258 Glut4 transporter facilitating glucose uptake (Biessels and Reagan, 2015). Thus, we  
259 examined transporter levels in our samples (**Figure 2A and B**). However, we did not find  
260 significant differences in Glut4 levels in any of the supplemented groups.

### 261 **BMFC+KOC Ameliorate Cellular Energy States and Increase Mitochondrial** 262 **Biogenesis in Hippocampus**

263       Energetic state levels in brain tissue are influenced by mitochondrial biogenesis,  
264 which can be dramatically damaged during aging. Thus, we first evaluated the  
265 intracellular levels of adenosine triphosphate (ATP) in hippocampal samples. We found  
266 that all experimental groups showed an increase in ATP levels, being significant in BMFC  
267 animals (**Figure 3A**). Interestingly, this improvement was not detected in cerebral cortex  
268 samples (**Figure 3B**), suggesting that supplementation with bioactive phospholipids  
269 differently affects brain areas at this level. Thus, we wanted to figure out whether this  
270 increased energetic state in hippocampus could be due to an augmented mitochondrial  
271 biogenesis. To achieve this, we carried out protein analysis expression of the five  
272 complexes (**Figure 3C**). Animals fed with both BMFC and KOC supplement increased  
273 the expression of proteins from all the complexes studied, suggesting that amelioration of

274 cell energy state is mediated by an increase in mitochondrial biogenesis. We also  
275 evaluated the expression of 70 genes corresponding to the five mitochondrial complexes  
276 and seven associated with the respiratory chain (not included in any complex) in the  
277 hippocampus. An increase in the expression of key genes involved in the complexes I,  
278 IV, and V (Fig. 3d) was detected by qRT-PCR, confirming the observed changes in  
279 protein levels.

280

### 281 **Mitochondrial biogenesis in BMFC+KOC animals is mediated through BDNF**

282 In order to determine whether the increased levels in mitochondrial complex proteins  
283 were mediated by the regulator of mitochondrial biogenesis, the peroxisome proliferator-  
284 activated receptor  $\gamma$  coactivator 1- $\alpha$  (PGC-1 $\alpha$ ), we explored the levels of this protein in  
285 hippocampal and cortical samples (**Figure 4A and 4B**). As seen in Figure 4A and 4B,  
286 PGC1- $\alpha$  was increased in BMFC+KOC rats in both brain areas. Since, this coactivator is  
287 regulated by the master metabolic regulator 5' AMP-activated protein kinase (AMPK),  
288 we further explored the levels of this kinase along with the NAD<sup>+</sup>-dependent type III  
289 deacetylase SIRT1 (Canto et al., 2009). Strikingly, although phosphorylated levels of  
290 AMPK were only increased in the KOC group both in hippocampus and cerebral cortex,  
291 SIRT1 levels were decreased in all experimental groups in the hippocampus and a trend  
292 (not significant) was observed in the cortex. As it has been described that PGC-1 $\alpha$   
293 activation requires both AMPK and SIRT1 (Canto et al., 2009), our results suggest that  
294 AMPK-SIRT1-mediated PGC1- $\alpha$  regulation is not taking place in our model.

295 Brain-derived neurotrophic factor (BDNF) has been implicated in neural ATP  
296 enhancement and in PGC-1 $\alpha$  activation (Marosi and Mattson, 2014a). Thus, we next  
297 analyzed BDNF levels in hippocampal samples (Figure 4A). Only BMFC+KOC  
298 supplemented animals showed an increase in BDNF levels, in accordance with the results

299 for PGC-1 $\alpha$ . However, although cortical BDNF was increased in all treated group, in this  
300 brain area it did not reach significant levels. This suggest that the incremented of  
301 mitochondrial biogenesis observed in hippocampus of BMFC+KOC rats could be  
302 mediated by BDNF. It has been proposed that BDNF exerts its actions through the  
303 mammalian target of rapamycin (mTOR), favoring local protein synthesis in dendrites  
304 (Takei et al., 2004). Thus, we examined mTOR levels in hippocampal and cortical  
305 samples. Increased levels of mTOR activity were detected in rats supplemented with  
306 BMFC+KOC, indicating that improvement in hippocampal energy state was mediated by  
307 mTOR through BDNF.

308

### 309 **Synaptic proteins are differently regulated in distinct brain areas**

310 Since mitochondrial biogenesis is necessary for BDNF to stimulate the formation of  
311 new synapses and to maintain the existing ones (Marosi and Mattson, 2014a), we wonder  
312 whether the observed changes in energy status after supplement treatment can be linked  
313 to synaptic signaling. Thus, we first analyzed the expression levels of genes encoding pre-  
314 and postsynaptic proteins in hippocampal samples (**Figure 5A**). Interestingly, syntaxin  
315 1A gene levels (*Stx1A*) were highly augmented in BMFC+KOC animals, whereas  
316 synapsin I (*Syn1*) and synaptotagmin 1 (*Syt1*) were not changed after the different  
317 treatments. We further examined postsynaptic structural proteins PDS95, PDS93 and  
318 SAP-102 levels (*Dlg4*, *Dlg2* and *Dlg3*, respectively) and found that, surprisingly, while  
319 *Dlg4* levels were increased in KOC rats, expression of the three genes were decreased in  
320 the BMFC+KOC group. In order to confirm these results, we developed western blots for  
321 the plasma membrane protein Stx1A and two other presynaptic proteins associated with  
322 synaptic vesicles, synaptobrevin 2 (Vamp2) and the chaperone  $\alpha$ -synuclein ( $\alpha$ -Syn)  
323 (**Figure 5B**). Although *Stx1A* mRNA levels was increased in the BMFC+KOC animals,

324 protein levels were not changed in any of the experimental groups. Only Vamp-2 was  
325 increased in all supplemented animals.

326 In the case of cerebral cortex samples, gene expression of the pre- and postsynaptic  
327 proteins showed increased levels in some of them (**Figure 5C**). *Stx1A* levels were  
328 significantly increased in BMFC+KOC rats, whereas *Syt1* mRNA was upregulated in all  
329 studied groups compared to that of control animals. At protein level (**Figure 5D**), Stx1a  
330 and  $\alpha$ -Syn was increased in KOC group and only  $\alpha$ -Syn was augmented in BMFC group.  
331 These results highlight different synaptic regulation in distinct brain areas.

332

### 333 **Discussion**

334 There is growing evidence that cognitive decline associated to aging can be  
335 partially prevented through the change of certain lifestyle factors, such as diet and regular  
336 exercise (Fontana et al., 2014; Daviglius et al., 2011). In fact, Mediterranean diet has been  
337 related with lower incidence of age-related diseases, such as AD and cardiovascular  
338 disease (Jackson et al., 2016; Estruch et al., 2013). Thus, dietary fats, such as those from  
339 olive oil, could act as key players in aging effects, ameliorating, for instance, insulin  
340 signalling in brain (Crespo et al., 2017a). Moreover, diet supplementation with PUFA,  
341 such as DHA, or the more available n-3 FAs associated to phospholipids, such as krill oil,  
342 could be a good approach in order to prevent aging (Wijendran et al., 2002; Konagai et  
343 al., 2013). Although milk fat globule membranes supplementation in infant and children  
344 seems to have certain neurodevelopment benefits (Hernell et al., 2016), their effects on  
345 the elderly is poorly characterized (Kim et al., 2015; Minegishi et al., 2016).

346

347 As insulin resistance has been largely related with age and its associated diseases  
348 (Akintola and van Heemst, 2015), we aimed to study brain insulin signaling in response

349 to dietary supplementation with bioactive phospholipids concentrates of krill oil and  
350 butter milk in aged rats. After three months of supplementation, although all groups of  
351 animals showed clear signs of peripheral insulin resistance, only the combination of KOC  
352 and BMFC was able to improve peripheral insulin sensitivity. In fact, both krill oil and  
353 MFGM have been previously shown to reduce insulin levels in type 2 diabetes and obese  
354 individuals, respectively (Lobraico et al., 2015; Demmer et al., 2016), suggesting that  
355 dietary FFA/phospholipids could help at this level. In order to know whether this  
356 amelioration in peripheral insulin resistance could also be detected at central nervous  
357 system level, we further explored insulin signaling in hippocampus and cerebral cortex,  
358 both brain areas implicated in cognitive processes. Interestingly, insulin signaling was  
359 improved in both structures, since the cascade of events was active when animals were  
360 supplemented with BMFC, KOC or both. These results highlight the importance of  
361 dietary fats in the compensation of disturbed insulin pathway observed in aging.

362

363       Considering that the energetic state level in brain is influenced by its mitochondrial  
364 content, we further explored brain energy balance. Interestingly, the hippocampus of  
365 supplemented rats—mainly with BMFC or the combination of KOC and BMFC—  
366 showed an increase in ATP levels, whereas no difference was observed in the cerebral  
367 cortex, suggesting that dietary fats induce different energy states in distinct brain areas,  
368 which is coherent with the observation that n-3 fatty acids incorporate into the various  
369 brain structures in a non-random, selected fashion (Lamaziere et al, 2011). The increased  
370 energy status of the hippocampus might be due to an increase in mitochondrial  
371 biogenesis, because both mitochondrial complex proteins and PGC-1 $\alpha$ , the key regulator  
372 of mitochondrial biogenesis, were augmented in BMFC+KOC-supplemented animals.

373 Remarkably, although we did not record higher ATP levels in the cerebral cortex of  
374 supplemented animals, BMFC+KOC rats presented increased levels of PGC-1 $\alpha$ ,  
375 suggesting that the combination of the two types of fat favors the increase of this  
376 transcription factor, in turn indicating an increase in mitochondrial biogenesis signaling  
377 in this brain area. Since all treated animals presented increased levels of the  
378 neurotrophin BDNF, upregulation of PGC-1 $\alpha$  appears to be mediated through it rather  
379 than AMPK-SIRT1. However, we only found a significant increase of BDNF in the  
380 hippocampus of BMFC+KOC animals. It is noteworthy that cerebral  
381 BDNF levels are quite low (Marosi and Mattson, 2014) and perhaps even a slight rise in  
382 BDNF levels could promote the action of PGC-1 $\alpha$  in the cerebral cortex.

383 BDNF stimulates mitochondrial biogenesis to form new synapses and to maintain the  
384 existing ones (Marosi and Mattson, 2014b). In fact, local protein synthesis at dendrite  
385 level is crucial in order to sustain synaptic plasticity, being BDNF the main modulator  
386 (Takei et al., 2004). Thus, BDNF facilitates synaptogenesis inducing mTOR pathway,  
387 which mediates signals for local protein synthesis (Takei et al., 2004). According to our  
388 previous results, in hippocampus, combined supplementation with both KOC and BMFC  
389 favored mTOR activation. Thus, animals fed with both fats presented all the necessary  
390 steps for synapse formation (Takei et al., 2004).

391 Although our results point to an improvement in synaptogenesis in hippocampal  
392 samples of BMFC+KOC-supplemented animals, when we explored synaptic genes and  
393 proteins, we did not find significant increases in this brain area. Surprisingly, cerebral  
394 cortices presented an induction of synaptic protein synthesis in all supplemented groups,  
395 although the highest levels were detected in the BMFC+KOC-supplemented group. As  
396 mentioned above, although BDNF and mTOR levels increased, statistical significance  
397 was not seen regarding controls, but it may be possible that such increase is enough to



398 improve synaptic protein synthesis at the dendrite level.

399 In summary, dietary supplementation with KOC and/or BMFC has improved  
400 peripheral and central insulin resistance, suggesting that they could be a good approach  
401 to delay this process. Moreover, n-3 fatty acids ingested as phospholipids ameliorate  
402 BDNF brain levels, as described before (Wu et al., 2004), favoring an improvement in  
403 energy state within neurons and facilitating both mitochondrial and protein synthesis,  
404 which are necessary for synaptic plasticity. Thus, dietary supplementation with n-3 FAs  
405 could protect local protein synthesis and energy balance within dendrites, favoring  
406 neuronal health and delaying cognitive decline associated to age-related diseases.

407

408

#### 409 **Author contributions**

410 JF, CV and FV designed the study. JTC, MCC, EBM, IPP, SB and AV performed  
411 experiments. MCC, JTC, EBR, CTZ, AD and FV wrote the manuscript. All authors  
412 approved the submission of the final version of the manuscript.

413

#### 414 **Conflict of interest**

415 The authors declare that no conflict of interest exist.

416


#### 417 **Acknowledgement**

418 Funding Information This study was supported in part by grants from the Spanish  
419 Ministerio de Economía y Competitividad (AGL2014-56464-R1 and AGL2014-54565-  
420 R2); by the Comunidad de Madrid through the BPrograma de actividades en tecnologías

421 (ALIBIRD-CM S2013/ABI-2728); and by the Castilla-La Mancha University through the  
 422 BPrograma de ayuda I+D a grupos emergentes^ (GI20173998) to EBR. AD lab is  
 423 supported in part by the Spanish Agencia Estatal de Investigación and European Feder  
 424 Funds (AGL2016-78922-R) and Fundación Ramón Areces (Madrid, Spain).


425

426 **Figure Legend**




427

428 **Figure 1.** Determination of insulin, glucose and insulin resistance index in rat serum.  
 429 Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat  
 430 globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid  
 431 (EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil;  
 432 BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. A) Glucose levels  
 433 expressed in mg/mL. B) Insulin levels expressed in mg/mL. C) homeostasis model  
 434 assessment ratio (HOMA-R), which is an index of insulin resistance. Values are  
 435 expressed as mean  $\pm$  SEM of the mean. \*Statistically significant difference regarding all  
 436 study groups at  $p < 0.05$ .




437

438 **Figure 2.** Western blot of proteins involved in the insulin-signaling pathway. A) Hippocampus samples B) Temporal cortex samples. IR $\beta$ : Insulin receptor; pIRS1: Phosphorylated insulin receptor substrate 1; IRS1: Insulin receptor substrate 1; IRS2: Insulin receptor substrate 2; p85: Subunit of phosphatidylinositol 3-kinase (PI3K); AKT: Serine/threonine protein kinase; pAKT 308: Phosphorylated AKT threonine 308; pAKT 473: Phosphorylated AKT serine 473; GLUT4: Glucose transporter 4; Control: Control group; BMFC: Concentrate of bioactive phospholipids from dairy fat globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) enriched in phospholipids from krill oil; BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. Values are expressed as mean  $\pm$  SEM of the mean. Statistically significant difference regarding all study groups at \*  $p < 0.05$ -0.005; \*\*  $p < 0.005$ -0.0005; \*\*\*  $p < 0.0005$ .




450 **Figure 3.** Measurement of cellular energy status and mitochondrial biogenesis. A & B) ATP levels expressed in pmol/ $\mu$ l. C) Western blots analysis involved in respiratory mitochondrial chain in hippocampus. D) Gene expression involved in mitochondrial respiratory chain pathway performed on hippocampus samples. ATP: adenosine triphosphate; Ndufab1: NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1; Slc25a10: solute carrier family 25 (mitochondrial carrier, dicarboxylate transporter), member 10; Atp5h: ATP synthase, H<sup>+</sup> transporting, mitochondrial F<sub>0</sub> complex, subunit D; Atp4a: ATPase H<sup>+</sup>/K<sup>+</sup> transporting alpha subunit; Cox8c: cytochrome c oxidase subunit 8C; Atp4b: ATPase H<sup>+</sup>/K<sup>+</sup> transporting beta subunit; Cox17: cytochrome c oxidase copper chaperone; Uqcrcb: ubiquinol-cytochrome c reductase binding protein; CI: Complex I; NC: does not belong to any complex; CIV: Complex IV; CV: Complex V; Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid

464 (EPA) and docosahexaenoic acid (DHA) enriched in phospholipids from krill oil;  
 465 BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. Values are  
 466 expressed as mean  $\pm$  SEM of the mean. Statistically significant difference regarding all  
 467 study groups at \*  $p < 0.05-0.005$ ; \*\*  $p < 0.005-0.0005$ ; \*\*\*  $p < 0.0005$ .



468

469 **Figure 4.** Western blot of proteins involved in mitochondrial biogenesis. A)  
 470 Hippocampus samples B) Temporal cortex samples. PGC1: Peroxisome proliferative  
 471 activated receptor, gamma, coactivator 1 alpha; pAMPK: phosphorylated AMPK;  
 472 AMPK: AMP-activated protein kinase; SIRT1: Sirtuin 1; BDNF: brain derived  
 473 neurotrophic factor; pmTOR: phosphorylated mechanistic target of rapamycin kinase;  
 474 mTOR: mechanistic target of rapamycin kinase; Control: control group; BMFC:  
 475 Concentrate of bioactive phospholipids from dairy fat globule membrane; KOC:  
 476 concentrate of omega-3 fatty acids (Eicosapentanoic acid (EPA) and docosahexaenoic  
 477 acid (DHA)) enriched in phospholipids from krill oil; BMFC+KOC: Mixing of the two  
 478 bioactive phospholipid concentrates. Values are expressed as mean  $\pm$  SEM of the mean.  
 479 Statistically significant difference regarding all study groups at \*  $p < 0.05-0.005$ ; \*\*  
 480  $p < 0.005-0.0005$ ; \*\*\*  $p < 0.0005$ .



481

482 **Figure 5.** Synaptic-proteins expression in both tissues. A) Expression analysis of genes  
 483 encoding proteins involved in the nerve synapse in hippocampus. B) Hippocampus  
 484 Western blot of proteins involved in the neurotransmission signaling. C) Expression  
 485 analysis of genes encoding proteins involved in the nerve synapse in Temporal cortex  
 486 samples. D) Temporal Western blot of proteins involved in the neurotransmission  
 487 signaling. STX1A: syntaxin 1A; SYN: synapsin I; SYT1: synaptotagmin 1; Dlg4: discs  
 488 large MAGUK scaffold protein 4 (PSD95); Dlg2: discs large MAGUK scaffold protein  
 489 2 (PSD93); Dlg3: discs large MAGUK scaffold protein 3 (SAP-102); Vamp-2: vesicle-  
 490 associated membrane protein 2;  $\alpha$ -Syn: synuclein alpha; Control: control group; BMFC:  
 491 Concentrate of bioactive phospholipids from dairy fat globule membrane; KOC:  
 492 concentrate of omega-3 fatty acids (Eicosapentaenoic acid (EPA) and docosahexaenoic  
 493 (DHA)) enriched in phospholipids from krill oil; BMFC+KOC: Mixing of the two  
 494 bioactive phospholipid concentrates. Values are expressed as mean  $\pm$  SEM of the mean.  
 495 Statistically significant difference regarding all study groups at \*  $p < 0.05$ - $0.005$ ; \*\*  
 496  $p < 0.005$ - $0.0005$ ; \*\*\*  $p < 0.0005$ .

497

## 498 References

- 499 Akintola AA, van Heemst D. 2015. Insulin, aging, and the brain: mechanisms and implications.  
 500 Front Endocrinol (Lausanne) 6, 13.  
 501 Bartke A. 2008. Insulin and aging. Cell Cycle 7, 3338-3343.  
 502 Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L. 2014. Krill oil supplementation  
 503 lowers serum triglycerides without increasing low-density lipoprotein cholesterol in  
 504 adults with borderline high or high triglyceride levels. Nutr Res 34, 126-133.  
 505 Bhat AH, Dar KB, Anees S, Zargar MA, Masood A, Sofi MA, et al. 2015. Oxidative stress,  
 506 mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight.  
 507 Biomed Pharmacother 74, 101-110.

508 Biessels GJ, Reagan LP. 2015. Hippocampal insulin resistance and cognitive dysfunction. *Nat*  
509 *Rev Neurosci* 16, 660-671.

510 Burgos-Ramos E, Chowen JA, Arilla-Ferreiro E, Canelles S, Argente J, Barrios V. 2011.  
511 Chronic central leptin infusion modifies the response to acute central insulin injection  
512 by reducing the interaction of the insulin receptor with IRS2 and increasing its  
513 association with SOCS3. *J Neurochem* 117, 175-185.

514 Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. 2009. AMPK  
515 regulates energy expenditure by modulating NAD<sup>+</sup> metabolism and SIRT1 activity.  
516 *Nature* 458, 1056-1060.

517 Castro-Gomez P, Garcia-Serrano A, Visioli F, Fontecha J. 2015. Relevance of dietary  
518 glycerophospholipids and sphingolipids to human health. *Prostaglandins Leukot Essent*  
519 *Fatty Acids* 101, 41-51.

520 Castro-Gomez P, Rodriguez-Alcala LM, Monteiro KM, Ruiz AL, Carvalho JE, Fontecha J.  
521 2016. Antiproliferative activity of buttermilk lipid fractions isolated using food grade  
522 and non-food grade solvents on human cancer cell lines. *Food Chem* 212, 695-702.

523 Crespo MC, Tome-Carneiro J, Pintado C, Davalos A, Visioli F, Burgos-Ramos E. 2017a.  
524 Hydroxytyrosol restores proper insulin signaling in an astrocytic model of Alzheimer's  
525 disease. *Biofactors* 43, 540-548.

526 Crespo MC, Tome-Carneiro J, Pintado C, Davalos A, Visioli F, Burgos-Ramos E. 2017b.  
527 Hydroxytyrosol restores proper insulin signaling in an astrocytic model of Alzheimer's  
528 disease. *Biofactors*.

529 Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, et al. 2011. Risk factors  
530 and preventive interventions for Alzheimer disease: state of the science. *Archives of*  
531 *neurology* 68, 1185-1190.

532 Demmer E, Van Loan MD, Rivera N, Rogers TS, Gertz ER, German JB, et al. 2016. Addition  
533 of a dairy fraction rich in milk fat globule membrane to a high-saturated fat meal  
534 reduces the postprandial insulinaemic and inflammatory response in overweight and  
535 obese adults. *J Nutr Sci* 5, e14.

536 Deutsch L. 2007. Evaluation of the effect of Neptune Krill Oil on chronic inflammation and  
537 arthritic symptoms. *J Am Coll Nutr* 26, 39-48.

538 Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. 2013. Primary  
539 prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 368,  
540 1279-1290.

541 FAO, WFP, IFAD, 2012. *The State of Food Insecurity in the World 2012*.

542 Economic growth is necessary but not sufficient to accelerate reduction of hunger  
543 and malnutrition, <http://www.fao.org/docrep/016/i3027e/i3027e.pdf>.

544 Fontana L, Kennedy BK, Longo VD, Seals D, Melov S. 2014. Medical research: treat ageing.  
545 *Nature* 511, 405-407.

546 Ghasemi R, Haeri A, Dargahi L, Mohamed Z, Ahmadiani A. 2013. Insulin in the brain: sources,  
547 localization and functions. *Mol Neurobiol* 47, 145-171.

548 Hernell O, Timby N, Domellof M, Lonnerdal B. 2016. Clinical Benefits of Milk Fat Globule  
549 Membranes for Infants and Children. *J Pediatr* 173 Suppl, S60-65.

550 Jackson PA, Pialoux V, Corbett D, Drogos L, Erickson KI, Eskes GA, et al. 2016. Promoting  
551 brain health through exercise and diet in older adults: a physiological perspective. *J*  
552 *Physiol* 594, 4485-4498.

553 Jicha GA, Markesbery WR. 2010. Omega-3 fatty acids: potential role in the management of  
554 early Alzheimer's disease. *Clin Interv Aging* 5, 45-61.

555 Kim H, Suzuki T, Kim M, Kojima N, Ota N, Shimotoyodome A, et al. 2015. Effects of exercise  
556 and milk fat globule membrane (MFGM) supplementation on body composition,  
557 physical function, and hematological parameters in community-dwelling frail Japanese  
558 women: a randomized double blind, placebo-controlled, follow-up trial. *PLoS One* 10,  
559 e0116256.

560 Kleinridders A, Ferris HA, Cai W, Kahn CR. 2014. Insulin action in brain regulates systemic  
561 metabolism and brain function. *Diabetes* 63, 2232-2243.

562 Konagai C, Yanagimoto K, Hayamizu K, Han L, Tsuji T, Koga Y. 2013. Effects of krill oil  
563 containing n-3 polyunsaturated fatty acids in phospholipid form on human brain  
564 function: a randomized controlled trial in healthy elderly volunteers. *Clin Interv Aging*  
565 8, 1247-1257.

566 Lobraico JM, DiLello LC, Butler AD, Cordisco ME, Petrini JR, Ahmadi R. 2015. Effects of  
567 krill oil on endothelial function and other cardiovascular risk factors in participants with  
568 type 2 diabetes, a randomized controlled trial. *BMJ Open Diabetes Res Care* 3,  
569 e000107.

570 Marosi K, Mattson MP. 2014a. BDNF mediates adaptive brain and body responses to energetic  
571 challenges. *Trends Endocrinol Metab* 25, 89-98.

572 Marosi K, Mattson MP. 2014b. BDNF mediates adaptive brain and body responses to energetic  
573 challenges. *Trends Endocrinol Metab* 25, 89-98.

574 Minegishi Y, Ota N, Soga S, Shimotoyodome A. 2016. Effects of Nutritional Supplementation  
575 with Milk Fat Globule Membrane on Physical and Muscle Function in Healthy Adults  
576 Aged 60 and Over with Semiweekly Light Exercise: A Randomized Double-Blind,  
577 Placebo-Controlled Pilot Trial. *J Nutr Sci Vitaminol (Tokyo)* 62, 409-415.

578 Pearson-Leary J, McNay EC. 2016. Novel Roles for the Insulin-Regulated Glucose Transporter-  
579 4 in Hippocampally Dependent Memory. *J Neurosci* 36, 11851-11864.

580 Riediger ND, Othman RA, Suh M, Moghadasian MH. 2009. A systemic review of the roles of  
581 n-3 fatty acids in health and disease. *J Am Diet Assoc* 109, 668-679.

582 Takei N, Inamura N, Kawamura M, Namba H, Hara K, Yonezawa K, et al. 2004. Brain-derived  
583 neurotrophic factor induces mammalian target of rapamycin-dependent local activation  
584 of translation machinery and protein synthesis in neuronal dendrites. *J Neurosci* 24,  
585 9760-9769.

586 Umegaki H, Makino T, Uemura K, Shimada H, Hayashi T, Cheng XW, et al. 2017. The  
587 Associations among Insulin Resistance, Hyperglycemia, Physical Performance,  
588 Diabetes Mellitus, and Cognitive Function in Relatively Healthy Older Adults with  
589 Subtle Cognitive Dysfunction. *Front Aging Neurosci* 9, 72.

590 Unger JW, Livingston JN, Moss AM. 1991. Insulin receptors in the central nervous system:  
591 localization, signalling mechanisms and functional aspects. *Prog Neurobiol* 36, 343-  
592 362.

593 Wijendran V, Huang MC, Diao GY, Boehm G, Nathanielsz PW, Brenna JT. 2002. Efficacy of  
594 dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain  
595 arachidonic acid accretion in baboon neonates. *Pediatr Res* 51, 265-272.

596 Wu A, Ying Z, Gomez-Pinilla F. 2004. Dietary omega-3 fatty acids normalize BDNF levels,  
597 reduce oxidative damage, and counteract learning disability after traumatic brain injury  
598 in rats. *J Neurotrauma* 21, 1457-1467.

599

600

601

602

603

604 **Table 1.** Experimental design of the study.

<i>Experimental Group</i>	<i>Control diet</i>	<i>Daily supplement (jelly)</i>
<b>Control</b>	<i>ad libitum</i>	70 mg refined olive oil
<b>BMFC</b>	<i>ad libitum</i>	70 mg of BMFC
<b>KOC</b>	<i>ad libitum</i>	70 mg of KOC
<b>BMFC+KOC</b>	<i>ad libitum</i>	70 mg of BMFC + 70 mg of KOC

605 Control: Control group; BMFC: Concentrate of bioactive phospholipids from dairy fat  
 606 globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid  
 607 (EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil;  
 608 BMFC+KOC: Mixing of the two bioactive phospholipid concentrates.

609

610 **Table 2.** Composition of lipidic classes of concentrates used to formulate the different  
 611 experimental diets.

	<i>Control</i>	<i>BMFC</i>	<i>KOC</i>	<i>BMFC + KOC</i>
<i>PE (%)</i>	-	0.55	15.66	5.16
<i>PI (%)</i>	-	-	1.92	0.77
<i>PS (%)</i>	-	-	16.92	6.79
<i>PC (%)</i>	-	99.45	38.74	72.48
<i>SM (%)</i>	-	-	26.76	14.79

612

613 Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat  
 614 globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid  
 615 (EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil;  
 616 BMFC+KOC: Mixing of the two bioactive phospholipid concentrates. %: Percentage of  
 617 different phospholipids; PE: phosphatidylethanolamine; PI: phosphatidylinositol; PS:  
 618 phosphatidylserine; PC: phosphatidylcholine; SM: sphingomyelin.

619

620 **Table 3.** Nutritional composition of the daily diet of the five experimental groups.

	<i>Control</i>	<i>BMFC</i>	<i>KOC</i>	<i>BMFC + KOC</i>
<i>Energy (Kcal)</i>	201,07	201,11	201,07	201,75
<i>Lipids (g)</i>	1,82	1,82	1,82	1,89
<i>Carbohydrates (g)</i>	32,10	32,11	32,10	32,11
<i>Fiber (g)</i>	2,05	2,05	2,05	2,05
<i>Proteins (g)</i>	11,01	11,01	11,01	11,01

621

622 Control: control group; BMFC: Concentrate of bioactive phospholipids from dairy fat  
 623 globule membrane; KOC: concentrate of omega-3 fatty acids (Eicosapentaenoic acid  
 624 (EPA) and docosahexaenoic acid (DHA)) enriched in phospholipids from krill oil;  
 625 BMFC+KOC: Mixing of the two bioactive phospholipid concentrates.



626 **Supplemental information (SI)**

627

628 **Supplemental Table S1.** Sequence of synapto-proteins primers analyzed

<b>Gene</b>		<b>Primers sequences</b>
<b>Presynaptic</b>	<b>Stx1A</b>	F: 5'- GCCCTGTTTGATTACGACAA-3'
		R: 5'- ACTCGGTTCTGAGCTATGAG
	<b>Syn1</b>	F: 5'- TGTCCCGAAAGTTTGTG-3'
		R: 5'- GCGTTCTCGGTAGTCT
	<b>Syt1</b>	F: 5'- CTTCTCCAAGCACGACATCA-3'
		R: 5'- CCACCCACATCCATCTTCTT -3'
<b>Postsynaptic</b>	<b>Dlg4</b>	F: 5'- TAGGGCCCTGTTTGATTACG-3'
		R: 5'- TGGCCTTTAACCTTGACCAC -3'
	<b>Dlg3</b>	F: 5'- GAGTTCCCGCATAAGTTTGG-3
		R: 5'- CGGACACGTCTAAGATGCAG -3'
	<b>Dlg2</b>	F: 5'- GTCGGAGGTTTCCCACAGTA-3'
		R: 5'- CTGTGCAGCTCCACCATCTA -3'

629 Stx1A: syntaxin 1A; Syn: synapsin I; Syt1: synaptotagmin 1; Dlg4: discs large MAGUK scaffold protein  
 630 4; Dlg2: discs large MAGUK scaffold protein 2; Dlg3: discs large MAGUK scaffold protein 3; F:  
 631 Forward; R: Reverse.

632

633 **Supplemental Table 2.** List of primary antibodies used to analyze the insulin signaling  
 634 pathway, neurotransmission and neurodegeneration.

<b>Antibodies</b>	<b>Molecular Weight (kDa)</b>	<b>Host</b>	<b>Company</b>
<b>p-thr308-AKT</b>	60	Rabbit	Cell Signaling *
<b>p-thr473-AKT</b>	60	Rabbit	Cell Signaling *
<b>AKT</b>	60	Rabbit	Cell Signaling *
<b>p-mTOR</b>	289	Rabbit	Cell Signaling *
<b>mTOR</b>	289	Rabbit	Cell Signaling *
<b>p-IRS1</b>	90	Rabbit	Santa Cruz Biotechnology **
<b>IRS1</b>	90	Rabbit	Santa Cruz Biotechnology **
<b>IRS2</b>	185	Mouse	Millipore *
<b>IRβ</b>	75-100	Mouse	Santa Cruz Biotechnology **
<b>p85 PI3K</b>	75-85	Mouse	Santa Cruz Biotechnology **
<b>p-AMPK α1/2</b>	60	Rabbit	Santa Cruz Biotechnology **
<b>AMPK α1/2</b>	63	Mouse	Santa Cruz Biotechnology **
<b>SIRT1</b>	120	Rabbit	Santa Cruz Biotechnology **
<b>PGC1</b>	90	Rabbit	Santa Cruz Biotechnology **
<b>GLUT2</b>	55-60	Rabbit	AD Internacional ***
<b>GLUT4</b>	50-63	Mouse	Santa Cruz Biotechnology **
<b>VAMP-2</b>	18	Mouse	Santa Cruz Biotechnology **
<b>Syntaxin 1</b>	35	Mouse	Santa Cruz Biotechnology **
<b>p-TAU</b>	50-80	Mouse	Cell Signaling *

<b>TAU-5</b>	46-80	Mouse	Santa Cruz Biotechnology **
<b><math>\alpha</math>-synuclein</b>	19	Mouse	Santa Cruz Biotechnology **
<b>BDNF</b>	14	Mouse	Novusbio ****
<b>UBB</b>	9	Mouse	Millipore *

635 \*(Madrid, Spain); \*\*(Heidelberg, Germany); \*\*\*(San Antonio, USA); \*\*\*\*(Abingdon,  
636 United Kingdom) Leyenda anticuerpos

637